SCHEMBL5038825

SCHEMBL5038825

Nc1ncnc2[nH]c(Sc3cc(OC(F)(F)F)ccc3I)nc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERBB2 P04626 9/20 0.41
HSP90AB1 P08238 4/20 0.41
HSP90AA1 P07900 7/20 0.38
DHFR P00374 1/20 0.35
SCN9A Q15858 2/20 0.34
CDC37 Q16543 1/20 0.33
NPC1 O15118 1/20 0.33
GMNN O75496 1/20 0.33
USP2 O75604 1/20 0.33
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
GAA P10253 1/20 0.33
CYP2C9 P11712 1/20 0.33
PKM P14618 1/20 0.33
ALOX15 P16050 1/20 0.33
NFKB1 P19838 1/20 0.33
SLC6A2 P23975 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4339904 0.85 ERBB2 (0.52) ERBB2HSP90AB1HSP90AA1CDC37
SCHEMBL5131165 0.83 HSP90AB1 (0.38) ERBB2HSP90AB1HSP90AA1LMNA
SCHEMBL3740870 0.81 ERBB2 (0.43) ERBB2HSP90AB1HSP90AA1DHFR
SCHEMBL3113829 0.80 SCN8A (0.38) DHFRPDE4D
SCHEMBL1669147 0.78 ERBB2 (0.39) ERBB2HSP90AB1HSP90AA1LMNA
SCHEMBL16487086 0.76 HSP90B1 (0.34) ERBB2HSP90AB1HSP90AA1DHFRSCN9A
SCHEMBL5044947 0.73 ERBB2 (0.37) ERBB2HSP90AB1HSP90AA1
SCHEMBL1966212 0.73 ERBB2 (0.53) ERBB2HSP90AB1HSP90AA1DHFR
SCHEMBL14467034 0.73 ERBB2 (0.41) ERBB2HSP90AB1HSP90AA1DHFR
SCHEMBL13079975 0.72 GAA (0.41) ERBB2HSP90AB1HSP90AA1NPC1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1962863-A2 ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 Conforma Therapeutics Corporation (US) 2008-09-03 EP disclosed
WO-2007075572-A2 ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 CONFORMA THERAPEUTICS CORPORATION (US) 2007-07-05 WO disclosed
US-20070129334-A1 Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 CONFORMA THERAPEUTICS CORPORATION (US) 2007-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129334-A1 Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 HSP90AB1, HSP90AA1, HSP90AB2P ERBB2 1609/4885HSP90AB1 1/4885HSP90AA1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.